Protocol Ledger

NCT06319456 · Phase III · RECRUITING

A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Interventional Phase III clinical trial protocol NCT06319456 sponsored by Ascentage Pharma Group in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-07 Enrollment: 344 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06319456
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)344 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06319456
Protocol FieldVerified Registry Value
NCT IdentifierNCT06319456
Consolidated Lead SponsorAscentage Pharma Group
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment344 participants (ESTIMATED)
Registered Start Date2024-04-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI